Gammagard is a brand of immunoglobulin therapy, a concentrated solution of antibodies collected from donated human plasma. It is FDA-approved to treat several conditions where the immune system either fails to produce enough protective antibodies or attacks the body’s own nerves. The drug comes in two formulations, Gammagard Liquid and Gammagard S/D, each approved for a slightly different set of conditions.
How Gammagard Works
Gammagard delivers a broad spectrum of ready-made antibodies (called IgG) that can neutralize bacteria and viruses. For people whose immune systems can’t produce enough of these antibodies on their own, an infusion essentially restocks the supply. The antibodies in Gammagard also interact with immune cells and can alter their activity, which is why the drug works for certain neurological and blood disorders, not just immune deficiencies. The exact mechanisms behind these immune-modulating effects are not fully understood.
Primary Immunodeficiency
The most common use for Gammagard is replacing missing antibodies in people with primary immunodeficiency (PI). These are inherited conditions where the body’s ability to fight infections is compromised because it doesn’t make enough protective antibodies. PI encompasses a range of diagnoses including common variable immunodeficiency, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Both Gammagard Liquid and Gammagard S/D are approved for PI in adults and children aged two and older.
Without treatment, people with PI face frequent, severe, and sometimes life-threatening infections. Regular Gammagard infusions keep antibody levels high enough to prevent these episodes. This is ongoing, long-term therapy rather than a one-time treatment.
Nerve Disorders: CIDP and MMN
Gammagard Liquid is approved for two chronic neurological conditions where the immune system mistakenly damages the protective coating around nerves.
In chronic inflammatory demyelinating polyneuropathy (CIDP), this nerve damage causes progressive weakness and reduced sensation, typically in the arms and legs. Gammagard is used to improve muscle function and reduce disability in adults with CIDP. The infusions help by modulating the immune response that drives the nerve damage.
Multifocal motor neuropathy (MMN) is a related but distinct condition that causes progressive weakness without the sensory symptoms seen in CIDP. Gammagard Liquid is the only immunoglobulin product specifically FDA-approved for MMN maintenance therapy. Most patients need high doses repeated every 4 to 8 weeks, often for several years. Notably, other immune-suppressing treatments that work for CIDP, such as corticosteroids and plasma exchange, do not help with MMN, making immunoglobulin therapy particularly important for these patients.
Kawasaki Disease in Children
Gammagard S/D is approved to prevent coronary artery aneurysms caused by Kawasaki disease, an inflammatory condition that primarily affects young children. Kawasaki disease causes inflammation in blood vessel walls throughout the body, and without treatment, it can lead to dangerous ballooning of the arteries that supply the heart. Immunoglobulin infusion given during the acute phase of the illness significantly reduces this risk.
Chronic ITP in Adults
Gammagard S/D is also approved for chronic idiopathic thrombocytopenic purpura (ITP) in adults, a condition where the immune system destroys platelets, the blood cells responsible for clotting. People with chronic ITP bruise easily and are at risk for serious bleeding. Gammagard infusions help raise platelet counts and prevent or control bleeding episodes.
Preventing Infections in Leukemia
Some adults with B-cell chronic lymphocytic leukemia (CLL) develop dangerously low antibody levels as the disease progresses, leaving them vulnerable to bacterial infections. Gammagard S/D is approved to prevent these infections in CLL patients who have low immunoglobulin levels or keep getting sick despite their cancer treatment.
Gammagard Liquid vs. Gammagard S/D
The two formulations share the PI indication but otherwise cover different conditions. Gammagard Liquid is the version used for nerve disorders (CIDP and MMN). Gammagard S/D covers Kawasaki disease, chronic ITP, and infection prevention in CLL. Your condition determines which formulation you receive.
One practical difference: Gammagard Liquid does not contain sucrose, a sugar that has been linked to kidney problems in some immunoglobulin products. This makes it a consideration for patients with existing kidney issues or diabetes.
Side Effects and Serious Risks
Gammagard carries a boxed warning, the FDA’s most serious safety alert, for two risks: blood clots (thrombosis) and kidney damage. Blood clots can occur even in patients with no known risk factors, though the risk is higher in older adults, people with a history of clotting, those on estrogen therapy, and anyone who has been immobile for extended periods. Kidney problems, including acute kidney failure, are more likely in patients over 65, those with pre-existing kidney disease, diabetes, or dehydration, and people taking other drugs that stress the kidneys.
Staying well hydrated before and during infusions reduces both risks. For higher-risk patients, infusions are given at slower rates. Common, less serious side effects of immunoglobulin infusions generally include headache, fatigue, chills, nausea, and reactions at the infusion site. These tend to be most noticeable during the first few infusions and often improve over time.
What Infusions Look Like
Gammagard is given as an infusion, either intravenously (into a vein) or, for certain indications, subcutaneously (under the skin). Intravenous infusions are typically given every 3 to 4 weeks and take several hours, depending on the dose and how fast the infusion rate can be safely increased. Subcutaneous infusions are given more frequently, often weekly, but each session is shorter and can be done at home after proper training.
Many patients start their infusions in a clinical setting so their care team can monitor for reactions. Once it’s clear the treatment is well tolerated, some patients transition to home infusions with the help of a specialty pharmacy and home nursing support. This shift can make a significant difference in quality of life for people on long-term therapy, since treatments may continue for years or even a lifetime depending on the underlying condition.